Qiagen NV opened at $50.35, in line with its previous close of $50.34. In the last trading session, the stock traded between $50.27 and $50.39. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Qiagen NV is now worth
$ 85.06
resulting in a loss of
$ 14.94 (14.94%)
Note: Past profits do not guarantee future returns.
Rating from 12 Analysts
Today's Change
$-0.05 (-0.09%)
Day High
$50.39
Day Low
$50.27
Day Open
$50.35
Prev Close
$50.34
Volume
20,66,441
1W Return
0.12%
1M Return
13.20%
3M Return
20.30%
6M Return
49.64%
1Y Return
6.58%
Market Cap ($ Mn)
10,365
PE Ratio
21.91
PB Ratio
2.65
PEG Ratio
6.02
ROE
11.86%
ROCE
8.93%
EPS (TTM)
$0.50
1 Week
0.12%
1 Month
13.20%
3 Months
20.30%
6 Months
49.64%
9 Months
-6.36%
Barclays downgrades Qiagen to Equal-Weight, cuts price target to $53
Barclays analyst Luke Sergott downgraded Qiagen from Overweight to Equal-Weight. Price target reduced from $55 to $53. Adjustment reflects updated analyst stance on the stock.
2 days agoCitigroup raises Qiagen price target to $52, maintains neutral rating
Citigroup raised Qiagen's price target from $45 to $52. The analyst maintained a Neutral rating on the stock. Price target increase amounts to $7 per share.
3 days agoQIAGEN and EQT agree on €46.50/share all-cash takeover offer
QIAGEN and EQT Private Equity agreed on an all-cash takeover offer at €46.50 per share. The offer represents a 40.3% premium to the unaffected share price of €33.15. Transaction values QIAGEN at approximately €10.8 billion in enterprise value. Closing expected in mid-2027 subject to regulatory clearances and 50% acceptance threshold.
8 days agoQIAGEN launches QIAsymphony Connect for automated clinical extraction
QIAGEN launches QIAsymphony Connect for automated clinical nucleic acid extraction. Platform supports up to 96 samples per run with full sample traceability. Backward compatible with existing QIAsymphony kits and consumables. Secured FDA (U.S.) and EUDAMED (Europe) regulatory listings. Initial customer orders received for liquid biopsy and oncology applications.
2mo agoQIAGEN appoints Jonathan M. Pratt as CEO effective September 2026
Jonathan M. Pratt appointed CEO of QIAGEN effective September 1, 2026. Thierry Bernard steps down as CEO and Managing Director at year-end. Company reaffirms third quarter and full-year 2026 financial outlook. Board continues strategic review with independent financial and legal advisors.
2mo agoQIAGEN secures FDA clearance for first U.S. bloodstream infection panel
QIAGEN secures FDA clearance for its first U.S. bloodstream infection panel, the QIAstat-Dx BCID GPF Plus AMR Panel. This move expands its syndromic testing portfolio to four major infectious disease areas. The panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in approximately one hour, supporting rapid treatment decisions for sepsis patients.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $709.18 | +0.71% | $2,62,217.18M | 33.49 | |
| $236.98 | +1.24% | $1,66,722.78M | 38.52 | |
| $436.00 | +2.73% | $62,846.78M | - | |
| $181.15 | -0.18% | $51,071.44M | 30.34 | |
| $480.07 | +0.67% | $47,165.92M | 104.98 | |
| $575.98 | +2.32% | $45,376.28M | 39.00 | |
| $275.06 | -1.43% | $45,329.89M | 32.52 | |
| $290.06 | +0.44% | $43,799.06M | 40.22 | |
| $1,718.61 | +1.19% | $34,435.79M | 31.52 | |
| $368.16 | +2.20% | $29,857.78M | 27.72 | |
| $252.92 | +2.97% | $27,826.01M | 25.77 | |
| $185.31 | +1.49% | $24,867.86M | - |
An investment of $100 made 5 years ago in Qiagen NV is now worth
$ 85.06
resulting in a loss of
$ 14.94 (14.94%)
Note: Past profits do not guarantee future returns.
